A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma.

Trial Profile

A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2012

At a glance

  • Drugs RAV 12 (Primary)
  • Indications Adenocarcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Apr 2012 Additional lead trial center identified as reported by ClinicalTrials.gov.
    • 19 Apr 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 19 Apr 2012 Actual end date (1 May 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top